Definium Therapeutics, Inc.
DFTXNext catalyst
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
Get an email about DFTX's next catalysts
Track Definium Therapeutics (DFTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout, Phase 3 readout).See the timeline
4 upcoming, 0 past
DFTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.55 | FQ end Sep/2026 | Call: amc
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) Phase 2 Est. Readout
Primary completion for MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) trial (NCT07303907) in Autism Spectrum Disorder
SourceDT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) Phase 2 Est. Readout
Estimated primary completion for DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) trial (NCT07303907) in Autism Spectrum Disorder. Topline data typically follows completion by weeks to months.
SourceDT120 Phase 3 Est. Readout
Primary completion for DT120 trial (NCT07592689) in Major Depressive Disorder
SourceMarket Overview
Stock performance and key metrics
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
WebsiteMM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
DT120
Major Depressive Disorder
MM-120 (LSD D-Tartrate)
Anxiety Generalized
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
MM120
Anxiety Generalized
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
MM-120
ADHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
DT120 | Phase 3 | Major Depressive Disorder | - | - |
MM-120 (LSD D-Tartrate) | Phase 2 | Anxiety Generalized | - | - |
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |
MM120 | Phase 2 | Anxiety Generalized | - | - |
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |
MM-120 | Phase 2 | ADHD | - | - |
Frequently asked questions
What is in Definium Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Definium Therapeutics, Inc.'s (DFTX) pipeline across Phase 3, Phase 2. Its lead program is DT120 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Definium Therapeutics, Inc.'s next FDA catalyst?→
Definium Therapeutics, Inc.'s (DFTX) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DFTX biotech catalysts?→
Add DFTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Definium Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.